



Excimer and Pulsed Dye Laser Treatment

Last Revision/Review Date: May 20, 2020

P&P # C.6.28

Policy

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee's specific plan document must be referenced. The terms of an enrollee's plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee's specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

Procedure

I. Excimer Laser Treatment of Psoriasis and Vitiligo

A. Documentation Required:

In order to facilitate the authorization process, referral requests must include the following:

1. Dermatologist documentation of mild to moderate localized psoriasis vulgaris (plaque psoriasis) or vitiligo of the face and neck.
2. Dermatologist documentation of percent body surface area of plaque psoriasis to be treated.
3. Dermatologist documentation of failed response to previous treatment.
4. Order from a dermatologist

B. Criteria for Medical Necessity-Psoriasis Initial Course of Treatment

Up to 13 excimer laser treatments using an FDA approved device is considered medically necessary for the treatment of mild to moderate localized plaque psoriasis if **BOTH** of the following are met:

1. Treatment area of localized plaque psoriasis affects 10% or less of body surface area;
- AND**
2. Failed response to 3 or more consecutive months of topical treatments from **at least 3** of the following:
 - a. Anthralin;
 - b. Corticosteroids;
 - c. Keratolytic agents;
 - d. Retinoids;
 - e. Tar preparations;
 - f. Vitamin D derivatives;
 - g. Calcineurin inhibitors.

C. Criteria for Medical Necessity-Vitiligo Initial Course of Treatment

Up to 13 excimer laser treatments using an FDA approved device is considered medically necessary for the treatment of vitiligo of the face and neck with documented failed response to 3 or more months of at least 2 of the following conservative treatments:

1. Topical or systemic corticosteroids;
2. Topical calcineurin inhibitors;
3. NB-UVB phototherapy or PUVA photochemotherapy.

D. Criteria for Medical Necessity-Subsequent Course of Treatment for Psoriasis and Vitiligo

Up to 13 excimer laser treatments per course and up to 2 additional courses per year is considered medically necessary for the treatment of mild to moderate localized plaque psoriasis of any body surface or vitiligo of the face and neck if there is documented, measurable response to treatment.

II. Pulsed Dye Laser (PDL) Treatment

A. Documentation Required

In order to facilitate the authorization process, referral requests must include the following:

1. Dermatologist documentation of the type of lesion and specific areas to be treated.
2. Dermatologist documentation of the treatment plan and anticipated outcome of treatment.
3. Documentation of symptoms and degree of functional impairment.
4. Order from a dermatologist.

B. Criteria for Medical Necessity-Pulsed Dye Laser (PDL)

Treatment with PDL is considered medically necessary for **EITHER** of the following conditions:

1. Treatment of congenital port-wine stains, glomangiomas that cannot be surgically removed, and infantile hemangiomas when they are located on the face or neck; **OR**
2. Treatment of superficial involuting, ulcerating or cavernous hemangiomas when **ONE** of the following is met:
 - i. The lesion compromises vital structures (e.g., nose, eyes, ears, lips); **OR**
 - ii. Is symptomatic (e.g., bleeding, painful, ulcerated); **OR**
 - iii. Results in a documented functional impairment.

III. Indications Considered Experimental, Investigational, or not Medically Necessary: (This list is not all inclusive.)

1. Excimer laser treatment of plaque psoriasis affecting greater than 10% of body surface area is considered not medically necessary.
2. Subsequent courses of excimer or pulsed dye laser treatment after failure to respond to the initial course of treatment is considered not medically necessary.
3. Excimer laser treatment of other forms of psoriasis including nail, scalp or palmoplantar psoriasis and pulse dye laser treatment of plaque or nail psoriasis is considered not medically necessary.
4. Excimer or pulsed dye laser treatment of the following dermatologic conditions is considered experimental or investigational (this list is not all inclusive):
 - a. Acne vulgaris
 - b. Atopic dermatitis

- c. Eczematous lesions
 - d. Granuloma annulare
 - e. Granuloma faciale
 - f. Herpes simplex labialis
 - g. Hidradenitis suppurativa
 - h. Jessner lymphocytic infiltration of skin
 - i. Lichen sclerosus
 - j. Lupus erythematoses
 - k. Melasma
 - l. Molluscum contagiosum
 - m. Morphea (scleroderma of the skin)
 - n. Mycosis fungoides
 - o. Onychia
 - p. Onychomycosis
 - q. Pilonidal sinus disease
 - r. Prurigo nodularis
 - s. Reticular erythematous mucinosis
 - t. Sarcoidosis
 - u. Spongiotic dermatitis
 - v. Vulval intraepithelial neoplasia
 - w. Xanthelasma
5. Excimer laser or pulsed dye laser treatment of the following dermatologic conditions are considered cosmetic and not medically necessary (this list is not all inclusive):
- a. Dyschromia (caused by café au lait spots, rashes, sunburn)
 - b. Rhinophyma
 - c. Rosacea
 - d. Spider angiomas
 - e. Striae distensae (stretch marks)
 - f. Telangiectasias

CPT/ HCPCS CODES:

96920	Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm
96921	250 sq cm to 500 sq cm
96922	over 500 sq cm
17106	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); less than 10 sq cm
17107	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); 10 sq cm to 50 sq cm
17108	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); over 50 sq cm

REFERENCES:

Adamic M, Pavlovic MD, Trollilus Rubin A, Palmetun-Ekback M, Boixeda P. Guidelines of care for vascular lasers and intense pulse light sources from the European Society for Laser Dermatology. Journal of the European Academy of Dermatology and Venereology. 2015;29(9):1661-1678.

de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM, Efficacy and Safety of Treatments for Childhood Psoriasis: a systemic literature review. J Am Acad Dermatol June 2010; 62: 1013-1030.

Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775-804.

Faurschou A, Olesen AB, Leonardi-Bee J, Haedersdal M. Lasers or light sources for treating port-wine stains. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD007152. DOI: 10.1002/14651858.CD007152.pub2.

Hayes, Inc. Comparative Effectiveness Review.

- Comparative Effectiveness Review of Laser Therapy for Psoriasis. Published April 25, 2019. Accessed April 1, 2020.
- Comparative Effectiveness Review, Laser and Light Therapies for Rosacea. Published January 25, 2018. Annual review December 21, 20218. Accessed April 1, 2020.

Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201.

Menter A, Strober BE, Kaplan DH, et al. Joint ADD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.

National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management. Published October 2012. Last updated September 2017. Available at: <https://www.nice.org.uk/guidance/cg153> Accessed April 1, 2020.

US Food and Drug Administration. 510(k) Summary. PhotoMedex inc. XTRAC Excimer Laser System, model AL 7000. 510(k) No. K003705. Rockville, MD: FDA; March 1, 2001.

van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD003262. DOI: 10.1002/14651858.CD003262.pub5.

Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K. Interventions for vitiligo. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD003263. DOI: 10.1002/14651858.CD003263.pub5.